Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC
Standard
Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC. / Becker, Jürgen C; Stang, Andreas; Hausen, Axel Zur; Fischer, Nicole; DeCaprio, James A; Tothill, Richard W; Lyngaa, Rikke; Hansen, Ulla Kring; Ritter, Cathrin; Nghiem, Paul; Bichakjian, Christopher K; Ugurel, Selma; Schrama, David.
In: CANCER IMMUNOL IMMUN, Vol. 67, No. 3, 03.2018, p. 341-351.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Epidemiology, biology and therapy of Merkel cell carcinoma:conclusions from the EU project IMMOMEC
AU - Becker, Jürgen C
AU - Stang, Andreas
AU - Hausen, Axel Zur
AU - Fischer, Nicole
AU - DeCaprio, James A
AU - Tothill, Richard W
AU - Lyngaa, Rikke
AU - Hansen, Ulla Kring
AU - Ritter, Cathrin
AU - Nghiem, Paul
AU - Bichakjian, Christopher K
AU - Ugurel, Selma
AU - Schrama, David
PY - 2018/3
Y1 - 2018/3
N2 - Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.
AB - Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.
KW - Journal Article
KW - Review
U2 - 10.1007/s00262-017-2099-3
DO - 10.1007/s00262-017-2099-3
M3 - SCORING: Review article
C2 - 29188306
VL - 67
SP - 341
EP - 351
JO - CANCER IMMUNOL IMMUN
JF - CANCER IMMUNOL IMMUN
SN - 0340-7004
IS - 3
ER -